Nurix Therapeutics (NRIX) Change in Acquisitions & Divestments (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $133.2 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $133.2 million, down 4.34% year-over-year; the trailing twelve-month figure through Feb 2026 was $611.5 million (up 20.96% YoY), and the FY2025 annual result was $617.5 million, up 34.39% from the prior year.
• Change in Acquisitions & Divestments fell to $133.2 million in Q1 2026 per NRIX's latest filing, from $179.8 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $179.8 million in Q4 2025 and troughed at $41.0 million in Q1 2023.
• A 5-year average of $106.6 million and a median of $99.8 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments slumped 30.23% in 2023, then soared 127.39% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $84.5 million in 2022, then retreated by 9.33% to $76.6 million in 2023, then soared by 108.21% to $159.5 million in 2024, then climbed by 12.73% to $179.8 million in 2025, then retreated by 25.95% to $133.2 million in 2026.
• Business Quant data shows NRIX's Change in Acquisitions & Divestments at $133.2 million in Q1 2026, $179.8 million in Q4 2025, and $156.2 million in Q3 2025.